| Market Capitalization (Millions $) |
219 |
| Shares
Outstanding (Millions) |
57 |
| Employees |
56 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-68 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Inozyme Pharma Inc
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for rare and debilitating disorders of the calcification and mineralization processes. The company was founded in 2015 by a team of experienced biotech executives and is headquartered in Cambridge, Massachusetts.
Inozyme Pharma is dedicated to developing therapeutic solutions for patients targeted with rare, life-threatening diseases. The so-called 'calcifying disorders' Inozyme is working to tackle are characterized by abnormal mineral deposits in soft tissues, joints and organs, causing severe morbidity and often death.
The leading focus of Inozyme's pipeline is the development of enzyme therapies that have the potential to safely and effectively restore a normal balance of mineral, calcium, and phosphate homeostasis.
Its leading therapy, INZ-701, is an enzyme replacement therapy designed to treat hypophosphatasia (HPP) and has already been granted orphan drug designation by the FDA in the US and the EMA in Europe, for both infantile and juvenile forms of HPP. HPP is a rare genetic disorder characterized by the abnormal mineralization of bones and teeth. In infants, the disease is lethal if not treated within the first year of life, and can result in a delayed ability to walk and bone fractures in older children and adults.
Inozyme's pipeline also includes INZ-801, a therapy that is aimed at treating ENPP1 deficiency disorder, a rare, inherited disorder that results in calcification problems of the joints and arteries. Inozyme has another preclinical program in development for Generalized Arterial Calcification of Infancy, another rare genetic disorder characterized by abnormal calcifications in the blood vessels.
The company has an experienced leadership team with a proven track record in the biotech industry. Its board of directors includes leaders in finance and healthcare and boasts extensive experience in developing new therapies at the leading pharmaceutical and biotech companies.
Inozyme Pharma is backed by leading institutional investors including Novo Ventures, Morningside Ventures, RA Capital Management, and Longitude Capital. The company has successfully raised over $126 million in funding since inception to advance its pipeline development.
Overall, Inozyme is a biopharmaceutical company with a powerful mission and a clear focus on developing therapeutic solutions to life-threatening rare diseases. The company has a dedicated leadership team, strong institutional support, and an innovative pipeline of enzyme replacement therapies that have the potential to change the standard of care for patients with calcifying disorders.
Company Address: 321 Summer Street Boston 2210 MA
Company Phone Number: 330-4340 Stock Exchange / Ticker: NASDAQ INZY
| INZY is expected to report next financial results on March 21, 2024. |
|
|
0.000%